Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Alveolar nitric oxide and asthma control in mild untreated asthma

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1- Inhibitor Deficiency Andrea Zanichelli, MD, Giulia Maria Azin, MD, Maddalena.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Allergen immunotherapy: A practice parameter third update

Fatty acids, inflammation, and asthma

Aleena Banerji, MD, Kimberly G. Blumenthal, MD, MSc, Kenneth H

Homozygous C1 inhibitor deficiency: The conclusion of a long search

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility

David A. Khan, MD Journal of Allergy and Clinical Immunology

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Activation of the ficolin-lectin pathway during attacks of hereditary angioedema Dorottya Csuka, PhD, Lea Munthe-Fog, PhD, Estrid Hein, MSc, Zsuzsanna.

Fatty acids, inflammation, and asthma

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Short-term prophylaxis in a patient with acquired C1-INH deficiency

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012 Anni Nørgaard Jeppesen, MD, Christian Fynbo.

Marcel Levi, MD, C. Erik Hack, MD, Marinus H. van Oers, MD

Hereditary angioedema: Safety of long-term stanozolol therapy

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

The National Biome Initiative: An allergy perspective

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Treatment of chronic autoimmune urticaria with omalizumab

Peter M. Wolfgram, MD, David B. Allen, MD

Successful treatment of idiopathic angioedema with ecallantide

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Reply Journal of Allergy and Clinical Immunology

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Phillip Lieberman, MD, David Golden, MD

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,

Sinonasal Papillomas and Natural Killer–Cell Deficiency

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Administration of Intravenous Immunoglobulin to a Patient with Hypogammaglobulinemia and Anti-IgA Antibodies Phillip Lieberman, MD, Rima Rachid, MD

News & Notes Journal of Allergy and Clinical Immunology

Higher incidence of pediatric anaphylaxis in northern areas of the United States William J. Sheehan, MD, Dionne Graham, PhD, Lin Ma, MS, Sachin Baxi,

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

New pathways for itching in patients with atopic dermatitis?

One step forward, 2 steps back: The enigma of preschool wheeze

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Thunderstorm-related asthma attacks

Measles and immunomodulation

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously Shilpa H. Desai, BS, MD, Akhil Chouksey, MD, John Poll, RN, Melvin Berger,

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

News & Notes Journal of Allergy and Clinical Immunology

The GILL study: Glycerin-induced local reactions in immunotherapy

Advances in pediatric asthma in 2007

Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor– associated angioedema Scott A. Hubers, MD, Kevin Kohm, MS, Shouzuo Wei,

Natural history of cow’s milk allergy

Susan L. Janson, DNSc, Kelly Wong McGrath, BA, Jack K

Primary prevention of asthma and allergy

Presentation transcript:

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD, Goda Choi, MD, Charles Picavet, MA, C. Erik Hack, MD Journal of Allergy and Clinical Immunology Volume 117, Issue 4, Pages 904-908 (April 2006) DOI: 10.1016/j.jaci.2006.01.002 Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Effect of self-administration of C1-inhibitor (C1-inh) concentrate on the initiation of relief and the complete resolution of symptoms after the onset of the angioedema attack. Controls refers to historical control subjects before the start of self-administration of C1-inhibitor concentrate. Journal of Allergy and Clinical Immunology 2006 117, 904-908DOI: (10.1016/j.jaci.2006.01.002) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Mean time to initiation of relief and complete resolution of symptoms in patients with hereditary and acquired deficiency of C1-inhibitor (C1-inh) after the onset of the angioedema attack when patients self-administer C1-inhibitor concentrate (striped bars) compared with the situation before they started self-management (open bars). Mean values and SDs are given. ∗P < .01, ∗∗P < .05. Journal of Allergy and Clinical Immunology 2006 117, 904-908DOI: (10.1016/j.jaci.2006.01.002) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Frequency of angioedema attacks per month after initiation of prophylaxis with C1-inhibitor (C1-inh) concentrate (striped bars) compared with the situation before the start of prophylaxis in patients (open bars) with hereditary and acquired C1-inhibitor deficiency. Mean values and SDs are given. ∗P < .001. Journal of Allergy and Clinical Immunology 2006 117, 904-908DOI: (10.1016/j.jaci.2006.01.002) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions